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Abstract 
Background: MDMA preferentially releases serotonin (5HT) but following repeated 
exposure there is a decrease in this MDMA-produced effect. At the same time, some 
studies suggest an increase in MDMA-produced dopamine (DA) release following 
repeated exposure. The sensitised DA response is often accompanied by sensitisation of 
MDMA-produced locomotor activity. Because DAergic mechanisms have been 
implicated in the positively reinforcing properties of MDMA, these neuroadaptations 
might be relevant to MDMA self-administration.  
Objectives: The main objective of this study was to determine whether MDMA self-
administration and non-contingent MDMA exposure differentially affected the 
development of sensitisation to MDMA-produced hyperactivity. Additionally, the 
relationship between MDMA-produced hyperactivity and changes in c-fos expression in 
DA terminal regions was determined.  
Methods: Triads of rats were designated ‘master’, ‘yoked MDMA’, or ‘yoked saline’. 
Lever press responding by the master rat resulted in an intravenous infusion of MDMA 
for both the master rat and the yoked MDMA rat, as well as an equal infusion of vehicle 
for the yoked control rat. Daily tests continued until a total of 350 mg/kg MDMA had 
been self-administered.  Three days following the last self-administration session, forward 
and vertical locomotion produced by MDMA (5.0 mg/kg, i.p) were measured during a 2 
hr test. Rats were sacrificed immediately following the behavioural test, and c-fos 
immunohistochemistry was measured. 
Results: Repeated MDMA exposure resulted in sensitised forward and vertical locomotor 
activity. Sensitisation of the increase in forward locomotion was produced only in rats 
that self-administered MDMA; non-contingent MDMA administration failed to sensitise 
this behavioural response. In contrast, sensitisation to MDMA-produced vertical activity 
was produced following both contingent and non-contingent MDMA exposure. C-fos 
expression was reduced in ventrolateral, and ventromedial areas of the dorsal striatum, as 
well as the infralimbic cortex, after MDMA exposure, regardless of whether the exposure 
was via self-administration or yoked administration. A selective decrease in c-fos 
expression in the nucleus accumbens (NAc) core and the cingulate cortex was produced 
by MDMA self-administration. There was a negative correlation between MDMA-
produced forward locomotor activity and MDMA-produced c-fos expression in the NAc 
 
 
8 
 
core, cingulate cortex and infralimbic cortex. A negative correlation between rearing 
activity and MDMA-produced c-fos expression in the NAc core, NAc shell, cingulate 
cortex, and infralimbic cortex was also found. 
Conclusions: These data provide evidence of behavioural sensitisation as a result of 
repeated MDMA exposure. Furthermore, MDMA-produced behavioural sensitisation was 
associated with a decrease in c-fos expression that was evident in the NAc and prefrontal 
cortex. Finally, region-specific changes in c-fos expression suggest an important role of 
neuroadaptations in the NAc core and the infralimbic cortex as a consequence of MDMA 
self-administration.  
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Introduction 
3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’) is a ring substituted 
amphetamine derivative with structural similarities to both stimulants and hallucinogens 
(Green, Mechan, Elliott, O'Shea, & Colado, 2003). MDMA was first synthesised and 
patented by Merck pharmaceuticals in 1914, in an attempt to discover a novel clotting 
agent (Freudenmann, Öxler, & Bernschneider‐Reif, 2006). It was not until the 1970s that 
the effects of MDMA were thoroughly investigated, when it was reported that MDMA 
produced psychoactive properties in humans (Shulgin & Nichols, 1978). In the 1980s, 
MDMA started to be used as an adjunct to psychotherapy. Because MDMA was reported 
to induce a feeling of being ‘touched within’ it was suggested that the drug would 
enhance the therapeutic experience (Shulgin, 1986). However it was not just in a clinical 
setting that MDMA became influential, its recreational use escalated in the early 1980s in 
the United States and abroad (Cohen, 1995). By 1985 the US drug enforcement agency 
classified MDMA a schedule I drug as a result of its high abuse potential, and lack of 
acceptance for use for clinical application (Green et al., 2003; Parrott, 2001).  
In New Zealand, MDMA is scheduled as a class B drug under the Misuse of 
Drugs Act, 1975. According to the World Drug Report compiled by the United Nations 
Office on Drugs and Crime, global prevalence of ecstasy use has been decreasing in 
recent years (United Nations Office on Drugs and Crime, 2014). However ecstasy use in 
Oceania continues to be among the highest, with a prevalence rate of 2.9 percent. In New 
Zealand there has been an increase in ecstasy use since the early 2000s (Wilkins & 
Sweetsur, 2008), and it is the second most widely used illegal drug in the country (Global 
Drug Survey, 2014). High rates of MDMA use in New Zealand are concerning because 
although MDMA is commonly considered a ‘safe’ drug (Kalant, 2001; Solowij, Hall, & 
Lee, 1992), numerous surveys indicate that the frequency of use increases over time for 
some users (Degenhardt, Bruno, & Topp, 2010; Soar, Turner, & Parrott, 2006) and some 
meet the criteria for a substance use disorder (Cottler, Womack, Compton, & Ben‐
Abdallah, 2001). 
Pharmacology of MDMA  
The primary neurochemical effect of MDMA is to increase the release of the 
neurotransmitter, serotonin (5HT) (Green et al., 2003; Nichols, Lloyd, Hoffman, Nichols, 
& Yim, 1982; Schmidt, 1987). The release of 5HT occurs via MDMA binding to, and 
reversing, the 5HT transporter, and by entering the neuron and reversing the action of the 
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vesicular monoamine transporter (Berger, Gu, & Azmitia, 1992; Rudnick & Wall, 1992). 
A vast amount of animal research has shown that MDMA increases levels of synaptic 
5HT as measured by microdialysis (Gough, Ali, Slikker, & Holson, 1991; Gudelsky & 
Yamamoto, 2008; Mechan et al., 2002; Sabol & Seiden, 1998), and consequently 
produces a marked reduction in 5HT tissue levels during the first few hours following 
administration (Gough et al., 1991; Schmidt, 1987). 
Like other drugs of abuse, MDMA also increases extracellular dopamine (DA) 
levels. This has been shown by in vivo microdialysis (Gough et al., 1991; Nash & 
Brodkin, 1991; Sabol & Seiden, 1998; Yamamoto & Spanos, 1988), and by in vitro 
experimental designs, using tissue slices (Johnson, Hoffman, & Nichols, 1986; Schmidt, 
1987). However, the extracellular increase in 5HT produced by MDMA is substantially 
greater than that of extracellular DA (Schenk, 2011). Baumann and colleagues (2008) 
provided one of many studies to support this claim by showing that an inter-peritoneal 
administration of MDMA (1.5 mg/kg) increased 5HT in the nucleus accumbens by 500%, 
but failed to alter synaptic DA. This difference was even greater following administration 
of a higher dose of MDMA (7.5mg/kg) where 5HT increased by 3000%, and DA 
increased by 500% (Baumann, Clark, Franken, et al., 2008).  
Effects of MDMA on humans 
MDMA has been reported to produce relaxation, euphoria, increased empathy, 
and feelings of closeness to others (Cohen, 1995; Green, Cross, & Goodwin, 1995; 
Solowij et al., 1992; Verheyden, Henry, & Curran, 2003; Vollenweider, Gamma, Liechti, 
& Huber, 1998). Adverse psychological effects also occur, with recreational users 
reporting acute feelings of anxiety, overstimulation, panic, and loss of personal control 
(Cohen, 1995; Davison & Parrott, 1997; Verheyden et al., 2003; Vollenweider et al., 
1998). In addition to these psychological effects, recreational doses of MDMA are 
associated with a number of physiological consequences, with the most reported adverse 
physiological response being hyperthermia (Cohen, 1995; Liechti, Baumann, Gamma, & 
Vollenweider, 2000). Experimental human studies confirmed a role of 5HT in these 
effects. For example, administration of a selective serotonin re-uptake inhibitor attenuated 
most of the subjective effects of MDMA, and a 5HT2 antagonist reduced MDMA-
produced perceptual changes and emotional excitation (Liechti, Baumann, et al., 2000; 
Liechti, Saur, Gamma, Hell, & Vollenweider, 2000; Liechti & Vollenweider, 2001).  
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MDMA use can also produce long term psychological and physiological deficits. 
These include depersonalisation, insomnia, depression, and flashbacks (Cohen, 1995). 
Functional deficits in memory (M. J. Morgan, 1999; Parrott, Lees, Garnham, Jones, & 
Wesnes, 1998; von Geusau, Stalenhoef, Huizinga, Snel, & Ridderinkhof, 2004), and 
executive functioning and reasoning abilities (Verdejo-Garcıa, López-Torrecillas, de 
Arcos, & Pérez-Garcıa, 2005; Wareing, Fisk, & Murphy, 2000), have also been reported. 
Neuroimaging studies have shown a reduction in the density of 5HT transporter sites 
(McCann, Szabo, Scheffel, Dannals, & Ricaurte, 1998; Ricaurte, McCann, Szabo, & 
Scheffel, 2000; Semple, Ebmeier, Glabus, O'Carroll, & Johnstone, 1999)  and reduced 
levels of the 5HT metabolite, 5-HIAA,  in MDMA users (Ricaurte, Finnegan, Irwin, & 
Langston, 1990). The decrease in 5HT transporter binding was positively correlated with 
the extent of the MDMA use, suggesting that repeated use might increase the risk of 5HT 
deficits (McCann et al., 1998).  
 Studies that investigate the effects of MDMA in humans provide invaluable 
information, but there are also considerable limitations. Firstly, polydrug use is common 
among ecstasy users, and so the attribution of long term effects of drug use specifically to 
MDMA cannot easily be determined (Green et al., 2003). Although researchers attempt to 
control for this by including the histories of subjects as a co-variate, this information is 
obtained by self-report and retrospective surveys. The reliability of these reports is likely 
to be compromised due to MDMA’s illegal status, functional deficits following MDMA 
use, or poor recall (Parrott, 2005; Topp, Hando, Dillon, Roche, & Solowij, 1999). 
Furthermore, it is difficult to attribute neuroadaptations to drug exposure rather than to a 
pre-existing condition (Green et al., 2003). Finally, there is limited information about 
purity or dose of MDMA consumed making it difficult to attribute long-term effects of 
drug use specifically to MDMA (Green et al., 2003).  
Animal studies are not plagued by the same confounds that often limit 
interpretation of studies with humans. A major challenge that animal studies can face, 
however, is the ability to generalise to the human condition.   
The effects of repeated MDMA 
As was observed in humans who consumed ecstasy, repeated exposure to MDMA 
produced dose-dependent 5HTergic deficits in non-human primates and rats (Battaglia et 
al., 1987; O'Hearn, Battaglia, De Souza, Kuhar, & Molliver, 1988; Scanzello, 
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Hatzidimitriou, Martello, Katz, & Ricaurte, 1993; Thomasius et al., 2003). It is worth 
noting that both dose and frequency of MDMA administration impacted the magnitude of 
5HT deficits. One study measured 5HT deficits following the administration of 4.0 mg/kg 
MDMA either daily for 4 days, twice-weekly for 8 weeks, or twice daily for 4 days, and 
found that only the latter dosing regimen decreased 5HT (O'shea, Granados, Esteban, 
Colado, & Green, 1998). Other studies have only found decreases in the density of 5HT 
reuptake sites after repeated exposure to high doses (20 mg/kg) of MDMA (Battaglia, 
Brooks, Kulsakdinun, & De Souza, 1988; Battaglia et al., 1987). Problematically, these 
regimens of regular, high doses have been criticised because human users rarely, if ever, 
experience this pattern of administration on initial exposure (Baumann & Rothman, 2009; 
Cole & Sumnall, 2003; De La Garza, Fabrizio, & Gupta, 2007; Meyer, Piper, & 
Vancollie, 2008). Most people consume 1-2 tablets during initial drug taking (De La 
Garza et al., 2007), raising questions concerning the validity of the findings from animal 
studies utilising repeated, high doses of MDMA. 
Under some experimental conditions, procedures that allow animals to self-inject 
drugs provide a more valid means of determining consequences of drug-taking in 
humans. Most drugs that are abused by humans are self-administered by animals, and 
drugs that are not abused by humans are not self-administered by animals (Griffiths, 
Bigelow, & Henningfield, 1980). Animal models of self-administration can, therefore, be 
used to more reliably investigate the consequences of repeated, chronic MDMA exposure, 
and the neurobiological mechanisms underlying its abuse. 
Drug self-administration 
 A number of routes of self-administration have been reported to successfully 
sustain drug-taking, including oral ingestion (Wikler, Martin, Pescor, & Eades, 1963), 
inhalation (Jarvik, 1967) intraperitoneal (Headlee, Coppock, & Nichols, 1955), and 
intracerebral (Olds & Olds, 1958). Intravenous (IV) self-administration is also a 
commonly used method (Schuster & Thompson, 1969). Weeks (1962) established the 
chronic IV catheter implant, which set the stage for studying the effects of IV drug self-
administration. Animals are surgically implanted with a chronic IV catheter and, 
following recovery, they are trained to perform an operant (e.g. lever press) in order to 
receive an IV infusion of the drug of interest (O’Connor, Chapman, Butler, & Mead, 
2011).  
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Self-administration studies uncovered an important role of DA in the reinforcing 
efficacy of drugs. DA antagonists attenuated the reinforcing effects of drugs of abuse as 
indicated by a dose-dependent compensatory increase in responding and a rightward shift 
in the dose-effect curve (Yokel & Wise, 1976). Furthermore, DA lesions blocked self-
administration, while lesions of other brain systems did not (Roberts & Koob, 1982). As a 
result of many of these seminal studies, it is now commonly accepted that voluntary self-
administration of drugs of abuse results from an increase in DA release in the mesolimbic 
DA system (Wise & Rompré, 1989).  
There is also ample evidence that 5HT is inhibitory to drug self-administration. 
Serotonin uptake inhibitors are not abused (Howell & Byrd, 1995; Roberts et al., 1999), 
and the reinforcing efficacy of amphetamine analogues was negatively correlated with 
5HT transporter affinity (Ritz & Kuhar, 1989). Based on these findings and because 
MDMA preferentially increases 5HT, MDMA would not be expected to be self-
administered. However, a number of studies have reported MDMA self-administration in 
non-human primates (Fantegrossi, Ullrich, Rice, Woods, & Winger, 2002; Lamb & 
Griffiths, 1987) and rats (Ratzenboeck, Saria, Kriechbaum, & Zernig, 2001; Schenk, 
Gittings, Johnstone, & Daniela, 2003).  
There are, however, a number of aspects of MDMA self-administration that 
differentiate it from the self-administration of other drugs of abuse. For example, the 
acquisition of MDMA self-administration was not dose-dependent; latency to meet a 
criterion for self-administration of a low dose was similar to latency to meet the criterion 
for self-administration of a higher dose  (Schenk et al., 2007). This contrasts with the 
well-documented dose-response functions for latency to acquisition of self-administration 
of other drugs of abuse. For example, the latency to acquire cocaine or amphetamine self-
administration was inversely related to the dose of drug (Carroll & Lac, 1997; Schenk et 
al., 1993). Additionally, the latency to acquisition of MDMA self-administration is 
considerably longer than is the latency to acquisition of self-administration of other drugs 
of abuse (Schenk et al., 2003). The most striking difference, however, is that only about 
50% of animals acquire MDMA self-administration (Schenk, Colussi-Mas, Do, & Bird, 
2012), which is considerably lower than what is generally seen in animals trained to self-
administer cocaine (Lile, Ross, & Nader, 2005) or amphetamine (Carroll & Lac, 1997). 
These data suggest that, at least initially, MDMA is a less efficacious reinforcer than 
other psychostimulant drugs.  
 
 
14 
 
In contrast to the acquisition profile of MDMA self-administration, once acquired, 
responding maintained by MDMA infusions became dose-dependent (Schenk et al., 2003; 
Schenk et al., 2007). This behavioural change was accompanied by neuroadaptations in 
both 5HTergic (Reveron, Maier, & Duvauchelle, 2010), and DAergic systems (Colussi-
Mas, Wise, Howard, & Schenk, 2010). Following repeated administration, the MDMA-
produced increase in synaptic 5HT was reduced (Reveron et al., 2010), and the increase 
in synaptic DA was increased (Colussi-Mas et al., 2010). Thus, with repeated exposure, 
the pharmacology of MDMA becomes similar to amphetamine or cocaine. 
Animals that self-administer large quantities of MDMA demonstrate behaviours 
consistent with some aspects of a substance use disorder. Substance use disorders are 
chronic relapsing disorders, and reinstatement of drug-seeking in animals has been used 
to explore the neuroadaptations that underlie the transition from drug use to drug abuse 
(De Wit & Stewart, 1981). Drug seeking can be produced by a priming injection of 
MDMA following the extinction of MDMA self-administration (Colussi-Mas et al., 2010; 
Schenk, 2008), and by exposure to stimuli that have been associated with self-
administered MDMA (Ball, Walsh, & Rebec, 2007; Schenk, 2008). DAergic mechanisms 
are also implicated in MDMA-seeking following extensive self-administration. 
Extinguished MDMA self-administration was reinstated by direct and indirect DA 
agonists (Schenk, Gittings, & Colussi‐Mas, 2011), but not by direct or indirect 5HT 
agonists (Schenk et al., 2011). Further, drug seeking was attenuated by DA antagonists 
(Schenk et al., 2011). These data further suggest that following MDMA self-
administration, MDMA begins to preferentially activate DAergic substrates to potentiate 
the drug seeking response.  
In summary, MDMA preferentially stimulates release of 5HT (Green et al., 2003). 
Following repeated exposure there is a decrease in MDMA-produced 5HT, and an 
increase in MDMA-produced DA (Colussi-Mas et al., 2010; Mayerhofer, Kovar, & 
Schmidt, 2001). It has been suggested that this increase in DA release underlies the 
development of high levels of MDMA self-administration (Schenk et al., 2011). 
Furthermore, following extensive self-administration of MDMA there is evidence of 
MDMA produced drug seeking, and sensitisation of DA release (Colussi-Mas et al., 
2010), suggesting that sensitisation of DA underlies the development of high levels of 
MDMA self-administration.  
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Behavioural Correlates of Sensitisation 
The sensitisation of DA release following repeated drug exposure is often 
mirrored by indices of behavioural sensitisation. A measure of behavioural sensitisation 
that is frequently employed when studying the effects of psychostimulants is locomotor 
activity. There are a number of studies that report a sensitised locomotor response 
following repeated exposure to various stimulants including cocaine (Kalivas & Stewart, 
1991; Post & Contel, 1983), and amphetamine (Kuczenski & Segal, 1988; Robinson & 
Becker, 1986). Repeated administration of MDMA also produced sensitisation of 
MDMA-produced forward locomotor activity (Ball, Wellman, Fortenberry, & Rebec, 
2009; Bradbury, Gittings, & Schenk, 2012; Colussi‐Mas & Schenk, 2008; Kalivas, Duffy, 
& White, 1998; Spanos & Yamamoto, 1989) and vertical locomotor activity (Lettfuss, 
Seeger-Armbruster, & von Ameln-Mayerhofer, 2013; Schenk & Bradbury, 2015).  
The acute hyperactive response to MDMA has been attributed, in part, to DAergic 
mechanisms since it was attenuated by neurotoxic DA lesions (Gold, Hubner, & Koob, 
1989), or DA antagonists (Ball, Budreau, & Rebec, 2003; Daniela, Brennan, Gittings, 
Hely, & Schenk, 2004). Repeated exposure to MDMA sensitised MDMA-produced 
hyperactivity and enhanced DA release as measured by in vivo microdialysis (Baumann, 
Clark, & Rothman, 2008). Enhanced synaptic DA also underlies increased rearing activity 
(Thiel, Müller, Huston, & Schwarting, 1999), although relatively fewer investigations of 
this behaviour have been conducted. Thus, as has been suggested for sensitisation to the 
behavioural effects of other drugs, sensitisation to the effects of MDMA have been 
attributed to sensitised DAergic mechanisms. 
Following repeated exposure animals also became sensitised to the reinforcing 
effects of stimulants, as indicated by decreased latency to acquire self-administration 
(Piazza, Deminiere, le Moal, & Simon, 1990; Suto et al., 2002), and an increase in 
motivation to self-administer drugs (Lorrain, Arnold, & Vezina, 2000; Mendrek, Blaha, & 
Phillips, 1998). Therefore, the neuroadaptations that underlie sensitisation of motor-
activating effects of MDMA might provide information concerning the neuroadaptations 
underlying the development of MDMA self-administration.  
Importance of contingency of drug exposure           
Most studies that examine behavioural sensitisation test the effect of the drug of 
interest following repeated experimenter-administration. Several studies, however, have 
suggested that the magnitude of neurochemical effects of repeated exposure might depend 
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on whether drug is experimenter-administered or self-administered (Dworkin, Mirkis, & 
Smith, 1995; Hemby, Koves, Smith, & Dworkin, 1997; Hemby, Martin, Dworkin, & 
Smith, 1995; Miguéns et al., 2008; Stefanski, Ladenheim, Lee, Cadet, & Goldberg, 1999). 
For example, higher extracellular levels of DA were produced following self-
administration of cocaine (Hemby et al., 1997), or amphetamine (Di Ciano, Blaha, & 
Phillips, 1996), when compared to the same amount administered non-contingently. Self-
administration of methamphetamine produced a significant reduction in D1- and D2-like 
receptors, but no significant difference was produced following non-contingent, yoked 
methamphetamine administration (Stefanski et al., 1999). Furthermore, DA transporter 
binding was significantly enhanced in animals that received contingent administration of 
cocaine, compared to animals that received the drug non-contingently (Miguéns et al., 
2008). Together, these studies suggest that the neuroadaptations produced by repeated 
exposure to drugs of abuse might depend on whether drug exposure is contingent or non-
contingent.  
One way to differentiate neuroadaptations that are produced by the 
pharmacological effects of the drug alone from those that are involved in the self-
administration procedure is to utilise a yoked self-administration paradigm in which 
animals are grouped into triads. Responding by a master rat results in an intravenous 
infusion of drug for the master rat and a yoked drug rat, as well as an equal infusion of 
vehicle for a yoked control rat. Thus, by using the yoked self-administration paradigm 
one can assess the pharmacological effects of the drug and distinguish any differences 
between the neurobiological consequences of drug exposure that is contingent, or non-
contingent. Figure 1 illustrates the basic mechanics of yoked self-administration. 
 
Figure 1. Yoked self-administration paradigm. The master rat (left) receives contingent 
drug delivery according to operant responding. The yoked drug rat (centre) non-
Yoked saline 
To computer that controls syringe pump 
To syringe pumps 
Yoked drug Master 
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contingently receives the same number and pattern of IV drug infusions as the master rat. 
The yoked saline rat (right) non-contingently receives IV vehicle injections that are 
identical in number and pattern to the drug injections. A computer-controlled, three-
chambered syringe pump enables the simultaneous delivery of these injections to all three 
rats. Image adapted from Haracz, Mash, and Sircar  (1999). 
Neuroadaptations resulting from self-administration  
The transition from drug use to drug misuse has often been attributed to the 
sensitisation of central DA mechanisms that occurs as a result of repeated exposure 
(Gardner, 1997). Repeated MDMA self-administration produced a sensitised DA 
response to MDMA (Colussi-Mas et al., 2010). The mechanism for this sensitised DA 
response is currently unknown, but neuroadaptive responses of certain brain regions are 
likely candidates.  
Previous research has suggested that neuroadaptations in the nucleus accumbens 
(NAc) play an important role in the development of drug taking (Wise, 2004) , whereas 
neuroadaptations in the dorsal striatum are invoked in the transition from drug self-
administration to compulsive drug self-administration (Everitt & Robbins, 2013). 
Furthermore, neuroadaptations in the prefrontal cortex (PFC) have been suggested to play 
an important role in drug-seeking (Kalivas, 2009). Therefore, it is likely different phases 
of self-administration may reflect neuroadaptations in different DA circuits.  
NAc: It is well established that the ventral striatum, including the NAc, plays a key 
role in mediating the reinforcing effects of stimulant drugs (Wise, 2004). This may not be 
surprising given that the NAc is a main projection site of DA-containing neurons from the 
ventral tegmental area. Previous research has highlighted the importance of the NAc since 
cocaine (McKinzie, Rodd‐Henricks, Dagon, Murphy, & McBride, 1999) and 
amphetamine (Phillips, Robbins, & Everitt, 1994) are self-administered directly into the 
rat NAc. Furthermore, a D1-like antagonist administered directly into the NAc attenuated 
the reinforcing effects of self-administered cocaine. In terms of effects of MDMA, 
various microdialysis studies have reported augmented release of DA in the NAc after 
repeated exposure to MDMA (Baumann, Clark, Franken, et al., 2008; Kalivas et al., 
1998). These data suggest that, much like other drugs of abuse, repeated exposure to 
MDMA produced a sensitised DA response in the NAc.  
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Dorsal striatum: The sensitised DA response in the NAc is thought to be 
important during the development of drug-taking, but the shift to compulsive drug-
seeking has been attributed to other neural circuits (Everitt & Robbins, 2005). It is 
important to acknowledge that while drug taking is often goal directed and develops 
because of the pleasurable subjective effects produced by the drug, following repeated 
exposure these pleasurable effects are reduced (Robinson & Berridge, 2000). 
Nonetheless, drug-taking often persists and drug-seeking develops. This transition from 
goal-directed behaviour to habitual, stimulus-response behaviour has been suggested to 
depend upon a switch of drug-produced effects from the ventral striatum (in particular the 
NAc) to the dorsal striatum (Everitt & Robbins, 2005, 2013; Vanderschuren, Di Ciano, & 
Everitt, 2005). The importance of DA in the dorsal striatum during drug-seeking is 
highlighted in a study that showed reduced cocaine-seeking behaviour following the 
administration of a DA antagonist directly into the dorsal striatum (Vanderschuren et al., 
2005). These data are further supported by the observation that cocaine-seeking under a 
second-order schedule is associated with an increase in extracellular DA in the dorsal 
striatum (Ito, Dalley, Robbins, & Everitt, 2002).  
Similar to cocaine, drug seeking in rats trained to self-administer MDMA was 
positively correlated with MDMA-produced DA release in the striatum (Colussi-Mas et 
al., 2010). In addition, repeated exposure to MDMA produced a decrease in 5HT levels in 
the striatum (Do & Schenk, 2013; O'shea et al., 1998; Scanzello et al., 1993; Schenk et 
al., 2007), as well as reduced 5HT release in the striatum (Baumann, Clark, Franken, et 
al., 2008).  
PFC: The PFC has also been suggested to play a key role in the development of 
drug-seeking (Kalivas, 2009). Along with the NAc, the PFC is one of the main projection 
areas of DA-containing cells of the ventral tegmental area (Sesack & Pickel, 1992). This 
pathway has been extensively studied and has been shown to play a crucial role in 
behavioural sensitisation to psychostimulants (Pierce & Kalivas, 1997; Vanderschuren & 
Kalivas, 2000). However, the PFC not only receives DAergic innervation from the VTA, 
it also sends major glutamatergic projections from the PFC to the NAc (Sesack & Pickel, 
1992). It has been suggested that these glutamatergic projections from the PFC play an 
important role in controlling drug-taking behaviour (Kalivas, 2009), and that drug use 
disrupts the excitatory glutamatergic outputs from the PFC resulting in compulsive drug-
seeking behaviour (Kalivas, 2009). The importance of the neural circuit is revealed by the 
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fact that the reinstatement of drug-seeking, and the associated increase in glutamate in the 
NAc, are both abolished by inactivation of PFC glutamatergic neurons that project to the 
NAc (McFarland, Lapish, & Kalivas, 2003).  
Of interest, ibotinic acidic lesion of the PFC prevented the development and 
expression of behavioural sensitisation following repeated MDMA exposure (Ramos, 
Goñi-Allo, & Aguirre, 2005). The inability of MDMA to produce behavioural 
sensitisation following impaired functioning of the PFC highlights the importance of this 
neural circuit in the development of MDMA-taking. 5HT receptors are also densely 
localised in the PFC and have been shown to modulate DA release (Alex & Pehek, 2007). 
Previous research suggests that there is a reduction in 5HT in the PFC following the self-
administration of MDMA (Do & Schenk, 2013; Schenk et al., 2007), and this finding 
aligns with what was found in former heavy ecstasy users (McCann et al., 1998). 
Furthermore, it has been  suggested that the prelimbic cortex, a sub-region of the PFC, 
plays an important role in MDMA-seeking (Ball & Slane, 2012). Together these data 
suggest that, much like other drugs of abuse, neuroadaptations in the PFC play an 
important role in the development of MDMA-seeking. 
Overall it is clear that ascending projections of midbrain dopamine neurons to the 
nucleus accumbens, dorsal striatum, and prefrontal cortex play an important role in 
modulating the reinforcing efficacy of drugs of abuse, including MDMA. It is likely that 
neuroadaptations within these structures are induced by repeated MDMA exposure. The 
shift from drug-taking to drug-seeking most likely represents a shift at the neural level. 
Although MDMA initially induces a large 5HTergic response, following repeated 
administration the 5HT response is reduced and the DA response is increased (Colussi-
Mas et al., 2010; Kalivas et al., 1998), with the result that MDMA becomes comparable 
to other drugs of abuse. If so, similar neuroadaptations may underlie the development of 
compulsive MDMA use (Schenk et al., 2011). 
Immediate Early Gene c-fos 
The immediate early genes are a group of transcription factors that play an 
important role in the regulation of brain development and function (Hughes & Dragunow, 
1995). In this large family of over 100 members, the proto-oncogene, c-fos, has been 
extensively mapped following a variety of manipulations as a measure of neural 
activation (Curran & Morgan, 1995). C-fos is expressed in neurons following the entry of 
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calcium through voltage-gated channels into the cell (J. I. Morgan & Curran, 1986), and 
so expression of c-fos in specific neurons often occurs following recent activation. Fos, 
the protein of c-fos, can be detected within neurons using immunohistochemical 
techniques (Menetrey, Gannon, Levine, & Basbaum, 1989; J. I. Morgan, Cohen, 
Hempstead, & Curran, 1987; Mugnaini, Berrebi, Morgan, & Curran, 1989), thereby 
allowing an in vivo map of cellular responses to a given stimulus.  
A number of studies have mapped the neural substrates mediating the long term 
effects of exposure to drugs of abuse by measuring changes in c-fos expression (Harlan & 
Garcia, 1998). Acute administration of cocaine (Ennulat, Babb, & Cohen, 1994; Graybiel, 
Moratalla, & Robertson, 1990; Hope, Kosofsky, Hyman, & Nestler, 1992; Moratalla, 
Elibol, Vallejo, & Graybiel, 1996; Steiner & Gerfen, 1993) and amphetamine (Graybiel et 
al., 1990; Jaber et al., 1995; Konradi, Leveque, & Hyman, 1996; Persico, Schindler, 
O'Hara, Brannock, & Uhl, 1993; Wang, Smith, & McGinty, 1995) stimulated a rapid 
increase in c-fos expression in a number of  brain regions, including the dorsal striatum, 
NAc and PFC. In comparison, more complex changes in c-fos expressions were seen after 
repeated drug administration. C-fos expression was reduced in the dorsal striatum, NAc 
and PFC, following repeated exposure to cocaine (Ennulat et al., 1994; Hope et al., 1992; 
Moratalla et al., 1996; Steiner & Gerfen, 1993; Todtenkopf & Stellar, 2000) or 
amphetamine (Jaber et al., 1995; Konradi et al., 1996; Persico et al., 1993). In the 
majority of these studies rats were tested within 24 hours of the last drug treatment. 
Following a longer withdrawal period the results are equivocal. For example, some 
studies report no change in c-fos expression in the striatum (Ostrander et al., 2003), while 
others report a sensitised c-fos induction (Norman, Lu, Klug, & Norgren, 1993). Thus, 
results of studies are difficult to compare due to widely varied drug treatment regimens 
and lengths of withdrawal.  
There was an increase in c-fos expression in the PFC and striatum, following 
cocaine (Daunais, Roberts, & McGinty, 1993; Gao, Limpens, Spijker, Vanderschuren, & 
Voorn, 2015; Larson et al., 2010; Neisewander et al., 2000; Zahm et al., 2010), and 
methamphetamine (Cornish, Hunt, Robins, & McGregor, 2012; Krasnova et al., 2013), 
self-administration, however the magnitude of the increase in c-fos expression was 
variable. For example, methamphetamine produced similar increases in c-fos expression 
in subjects with extensive methamphetamine self-administration experience, and yoked 
saline controls (Cornish et al., 2012), while c-fos expression in response to cocaine was 
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lower in cocaine self-administration subjects, compared to yoked saline controls (Larson 
et al., 2010; Zahm et al., 2010). Furthermore, Larson and colleagues (2010) suggest that 
yoked cocaine animals only showed reduced c-fos expression in the dorsal striatum.  
There are a limited number of studies that have investigated the changes in c-fos 
expression as a result of MDMA exposure, and all of the available data focus on non-
contingent administration of MDMA. Nevertheless, these studies indicate that acute 
administration of MDMA increased c-fos expression in a number of brain regions, 
including the PFC, NAc, and dorsal striatum (Colussi‐Mas & Schenk, 2008; Dragunow, 
Logan, & Laverty, 1991; Hargreaves, Hunt, Cornish, & McGregor, 2007; Hashimoto, 
Tomitaka, Narita, Minabe, & Iyo, 1997; Stephenson, Hunt, Topple, & McGregor, 1999; 
Won et al., 2003). Furthermore, c-fos expression was attenuated in various brain regions 
following repeated exposure to MDMA (Colussi‐Mas & Schenk, 2008). More research 
needs to be done in order to understand the neuroadaptations that occur following 
repeated exposure to MDMA, particularly following contingent exposure. Furthermore, 
by correlating changes in c-fos expression with behavioural data it is possible to reveal 
changes in brain regions that are functionally relevant.   
The present study 
 The present research was undertaken to determine whether the contingency of 
chronic exposure to MDMA would produce differential changes in the activation of 
neural populations. Firstly, in an attempt to replicate previous research, forward and 
vertical locomotor activity were examined following MDMA self-administration and 
non-contingent MDMA administration. Then the distribution of c-fos expression was 
examined in order to determine whether c-fos expression would differ between rats that 
self-administered MDMA, and rats that received the same amount of MDMA non-
contingently. Lastly, forward and vertical locomotor activity were correlated with c-fos 
expression in order to investigate whether the behavioural data could be explained by 
changes in c-fos expression in specific brain regions.  
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Methods 
Subjects 
Sprague-Dawley rats (n=81) bred in the vivarium at the Victoria University of 
Wellington, New Zealand were used. All experiments were approved by the Animal 
Ethics Committee of Victoria University of Wellington. Rats were housed in groups of 
four until reaching weights of 290-330g, thereafter they were housed individually in 
hanging polycarbonate boxes. The housing facility was temperature- (19-21°C) and 
humidity- (55%) controlled and maintained on a 12h light/dark cycle (lights on at 0700). 
All testing was completed during the light cycle and rats had free access to food and 
water except during testing. 
 
Surgery 
Rats were deeply anesthetised using a combination of ketamine (90mg/kg, IP) and 
xylazine (9mg/kg, IP). The scalp and right side of the chest were shaved and swabbed 
with ethanol (75%) and vetadine. Eye lubricant was also used to prevent drying. An 
incision was made on the skull and the tissue was removed before an incision was made 
above the right external jugular vein. The vein was isolated and a length of silastic tubing 
was inserted into the vein and subcutaneously passed to an exposed section of the skull. 
The distal length of the catheter, comprising a 2cm piece of 22 gauge stainless steel 
tubing was attached to the skull using embedded jeweller’s screws and dental cement. An 
electrolyte replacement (Hartmann’s solution, 12ml, s.c) as well as an analgesic 
(carprofen, 5.0mg/kg, s.c) was administered following surgery. Post-operative care on the 
two days following surgery consisted of carprofen (5.0mg/kg, s.c) to reduce pain and 
inflammation, and catheters were infused with 0.15-0.2 ml of solution containing heparin 
(30IU/ml) to prevent coagulation and penicillin (250 000 IU/ml). Self-administration 
testing began at least 5-7 days after surgery, once pre-surgery weight was reached. A 
weekly test of the catheter patency was conducted by administration of pentobarbital 
(20mg/kg, i.v).  Immediate lack of the automatic righting reflex confirmed patency.  
 
Apparatus 
Self-administration testing was conducted in a temperature- (19-21°C) and 
humidity- (55%) controlled environment using operant chambers (Medical Associates, 
ENV-001) equipped with two levers and a stimulus light. Rats were randomly assigned to 
groups of three and assigned as ‘master’, ‘yoked MDMA’ or ‘yoked saline’. Depression 
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of the right lever (i.e. the “active” lever) by the master rat resulted in a 12 second infusion 
of MDMA (0.1ml) for the master and yoked MDMA rats or an infusion of vehicle 
(3IU/ml heparinised saline) for the yoked control rat. Infusions were paired with the 
illumination of a light stimulus located above the lever. Depression of inactive lever had 
no programmed consequence for any rat. Both active and inactive lever responses were 
recorded for all rats.  
Each day before testing, catheters were flushed with 0.2mls of the heparin-
penicillin solution and the exposed metal tubing was connected to a 20ml drug syringe 
through a length of micro bore tubing. The tubing was connected through a steel spring 
for protection and fed through a swivel mechanism (Harvard Apparatus) to the syringe 
which was loaded into a pump (Razel, Model A. Motor: 1rpm). All drug infusions and 
data collection were controlled by Med Associates software.  
Locomotor activity was conducted in clear Plexiglas chambers (Med Associates 
Inc., USA; model ENV-515) measuring 42 x 42 x 30cm, located within sound attenuating 
boxes. Forward locomotion was measured using two sets of sixteen infra-red beams and 
sensors spaced evenly along the side of each box produced squares measuring 25 x 
25mm. The interruption of three adjacent beams was recorded as one activity count. In 
addition, vertical locomotion (rearing) was measured using a second set of identical infra-
red sensors located 14cm above the floor of the chamber. A white noise generator was 
used during the experiments to mask any outside noise. At the end of each session, 
chambers were wiped with Virkon ‘S’ disinfectant (Southern Veterinary Supplies, NZ) to 
control for any olfactory confounds. All experiments were run in the dark except for a red 
light that was used to illuminate the room during drug administration.  
Procedure 
Self-administration: Rats were weighed and catheters were flushed with the 
penicillin/heparin solution. The rats were then placed in the operant chamber boxes and 
connected to the tubing/spring apparatus for self-administration training. Rats assigned to 
the ‘master’ group were trained to self-administer MDMA, whereas rats assigned to the 
‘yoked MDMA’ and ‘yoked saline’ groups were both manually connected to the light and 
pump mechanism of the master rat.  
Training: Self-administration sessions were conducted during 2hr sessions, 6 days 
per week. Each self-administration session began with an experimenter-delivered infusion 
of drug to clear the line of penicillin solution. Thereafter, depression of the active lever 
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resulted in an infusion of MDMA (1.0 mg/kg) to the master and yoked MDMA rats, and 
saline to the yoked saline rats, according to a Fixed Ratio 1 (FR1) schedule. Tests 
continued until a total of 90 infusions (90 mg/kg) had been self-administered by the 
master rat or 25 days, whichever came first. A total of 15 master rats, and the associated 
triads, failed to meet this criterion and were not included for further testing (Aronsen, 
Bukholt, & Schenk, 2016; Bradbury et al., 2014; Schenk et al., 2012). For the remaining 
36 rats (12 triads) the dose was reduced to 0.5mg/kg until an additional 150 infusions 
were administered. When responding varied by less than 20% over three consecutive days 
the reinforcement schedule was then changed to FR2. Then once responding on the FR2 
schedule had stabilised (varied by less than 20% over three consecutive days) the 
reinforcement schedule was changed to FR5 and rats remained on this schedule until a 
total of 350 mg/kg MDMA had been self-administered.   
A total of 12 triads met the initial criterion of 90 infusions of MDMA (1.0 
mg/kg/infusion). Some triads did not proceed for various reasons: three triads due to loss 
of catheter patency, three triads due to MDMA toxicity, and two triads due to an inner ear 
infection. This is an abnormally high attrition rate, but only complete triads were included 
in the current study. The remaining four triads completed testing and self-administered 
350 mg/kg MDMA. The training stage varied but an average of 14.5 (SD = 3.52) daily 
sessions was required to meet the initial criterion of 90 mg/kg and an additional 15.75 
(SD = 0.50) days was required to meet the subsequent 350 mg/kg criterion.  
Locomotor activity:  Horizontal and vertical activity were measured during three 
daily test sessions that commenced the day following the last session. On each day of 
testing the rats were habituated to the chamber for 30 minutes before receiving an 
injection of either saline vehicle (i.p) on the first two days, or MDMA (5 mg/kg, i.p) on 
the test day. After the injection, animals were immediately returned to the activity 
chambers and activity was then measured for 2 hours post-injection. This time frame was 
used because c-fos expression peaks between 1 to 3 hours after a stimulation (Kovács, 
1998). After both habituation sessions the rats were returned to the home cage, but on the 
test days animals were euthanized immediately after the activity session. Testing was 
completed between 0700 and 1000. 
Rats were deeply anesthetised with sodium pentobarbital (50mg/kg, i.p) and 
perfused transcardially with 60ml of 0.1% heparinised saline followed by 200ml of 4% 
paraformaldehyde solution in 0.1M phosphate buffer (PB) (pH 7.2). Perfusions were 
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performed using a perfusion pump (EYLA micro tube pump MP-3, Tokyo Rikakikai Co., 
Ltd, Tokyo, Japan) at a speed of 1450ml/hr (or 24.16 ml/min). Brains were then rapidly 
removed, placed in 4% paraformaldehyde fixative overnight, cryoprotected in 20% 
glycerol containing 0.1M PB and 0.05% sodium azide at 4°C, before being frozen for 
4min in isopentane at -40°C. Brains were stored at -80°C until further processing.  
Immunohistochemistry: Coronal sections (35μm thick) were cut on a sliding 
microtome (Microm HM 450) connected to a freezing unit (Microm KS 34, Microm 
International GmbH part of Thermo Fisher Scientific, Auckland, New Zealand) chilled to      
-40°C. Tissue slices were stored in 0.1M phosphate buffered saline (PBS) with 0.05% 
sodium azide at 4°C until immunological staining. Areas of interest included the dorsal 
striatum, the nucleus accumbens, and the prefrontal cortex. These areas were selected 
using images from Paxinos & Watson’s Rat Brain Atlas (Paxinos & Watson, 2005).  
c-fos: The revelation of c-fos positive nuclei was conducted as per the protocol 
reported in Colussi‐Mas and Schenk (2008). Free-floating sections were washed in PBS 
containing 0.3% Triton X-100 (PBST) (3x10min) and incubated overnight with the 
primary rabbit anti-Fos antibody  (Ab-5; Calbiochem, EMD Biosciences, Darmstadt, 
Germany) diluted to 1:20000 in PBST and 1% bovine serum albumin. The anti-Fos 
antibody was raised against a synthetic peptide (SGFNADYEASSSRC) which 
corresponds to amino acids 4-17 of the human Fos protein. It recognises the ~55 kDa c-
Fos and the ~62 kDa v-Fos proteins, and does not cross-react with the ~39 kDa Jun 
protein (manufacturer’s data sheet). During washing and incubation, sections were gently 
agitated on a tilting rocker at room temperature.  
The following day, sections were washed with PBST (3 x 10mins) before being 
incubated for 90 min with the secondary biotinylated goat anti-rabbit antibody (Vector 
Laboratories, Burlingame, CA, USA) diluted 1:1000 in PBST. This was followed by 
another three washes in PBST (3x10mins) and a 60 min incubation with a preformed 
avidin-biotinylated horseradish peroxidase complex diluted 1:1000 in PBST. Sections 
were washed in PBST (3x10mins) and c-fos was revealed by a reaction with 50mM Tris 
HCl (pH 7.4) buffer, containing 0.02% 3,3'-diaminobenzidine, 0.8% nickel chloride and 
0.003% H2O2, resulting in blue-black staining precipitate. This reaction was stopped with 
a further three washes in PBST. Finally, the sections were mounted on gelatin-coated 
slides and left to dry overnight. The slides were then stained with neutral red, rinsed in 
distilled H2O, dehydrated in EtOH (70%, 95% x 2, 100% x 2) and rinsed twice in Histo-
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Clear. The slides were then coverslipped with DePeX mounting medium. A control 
without the primary antibody was stained to ensure nonspecific staining was not present. 
Cell counts and analysis of immunohistochemical data: Sections were magnified 
using an Olympus BX-51 microscope equipped with a MBF Biosciences camera (CX 
9000) (x 20 magnification) and computerised image analysis system Neurolucida (MBF 
Biosciences, v. 8). Cells with dark blue or black nuclei were manually counted. 
The distribution of positively stained nuclei for the c-fos antibody was 
determined. For each structure the number of Fos-immunoreactive (IR) cells was 
bilaterally counted in sections taken at 210-µm intervals, according to the rostrocaudal 
extension of the structure. For each structure a template was determined according to its 
shape and size (Fig. 2). The density of Fos-IR cells was calculated as the number of FOS-
IR cells/mm2 for each section. An average was then calculated for all sections within a 
structure for each rat. 
 
  
Figure 2. A schematic representation of the template used to quantify Fos-
immunoreactive cells. Adapted from Paxinos and Watson (2005). 1. Cingulate cortex; 2. 
Prelimbic cortex; 3. Infralimbic cortex; 4. Dorsal striatum, dorsolateral part; 5. Dorsal 
striatum, dorsomedial part; 6. Dorsal striatum, ventrolateral part; 7. Doral striatum, 
ventromedial part; 8. Nucleus accumbens core; 9. Nucleus accumbens shell. 
Drugs 
MDMA-HCl (ESR, Porirua, New Zealand) for self-administration was dissolved 
in a sterile solution of heparinised saline (3IU heparin, 0.9% NaCl). MDMA for non-
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contingent injections was dissolved in sterilised saline. Intravenous infusions were 
administered at a volume of 0.1 ml/kg and intraperitoneal injections were 1.0 ml/kg. All 
drug doses were calculated based on salt weights.  
 
Data Analysis 
Data were analysed using SPSS statistics package (SPSS Inc.; version 19.0 for 
Windows 7). An alpha level α=.05 was adopted for all analyses. Where appropriate, post 
hoc tests were conducted using the Tukey HSD method. To examine the effect of 
condition on lever responding, a 3(group) x 2 (lever) repeated measures analysis of 
variance (ANOVA) was used. Condition (master, yoked, control) was the between 
subjects factor, and lever (active, inactive) was the within subjects factor. 
To determine whether MDMA increased locomotor activity relative to saline, 
forward and vertical locomotor activity were assessed using separate analyses for master, 
yoked MDMA and yoked saline rats by a 2 (0, 5 mg/kg) x 30 (time) repeated measures 
ANOVA. The effect of MDMA exposure on forward and vertical locomotor activity was 
assessed by a 3 (master, yoked, control) x 30 (time) mixed model ANOVA, with time as 
the within subjects factor. The effect of MDMA exposure on c-fos density was assesed 
using a one-way ANOVA for each sub-region.  
Correlations between the density of Fos-IR cells and total  forward locomotor 
activity, as well as correlations between the density of Fos-IR cells and total vertical 
locomotor activity, were obtained using Pearson’s correlation. For each rat the density of 
Fos-IR was plotted against the corresponding value for total forward locomotor activity 
counts, or total vertical locomotor activity counts.  
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Results 
Part I: Behavioural effects of MDMA  
Self-administration 
The effect of self-administration condition (master, yoked, control) lever 
responding (active, inactive) over the last 5 days self-administration is shown in figure 3. 
ANOVA revealed a significant interaction between lever and self-administration 
condition (F(2,9) = 121.46, p<.05), as well as a main effect of lever (F(1,9) = 126.76, 
p<.05), and self-administration condition (F(2,9) = 67.51, p<.05). Post hoc analyses 
showed a significant preference for the active lever in the master condition, which was 
not seen in the yoked MDMA or yoked saline conditions. 
 
 
Figure 3. The effect of self-administration condition on lever responding. Bars represent 
average responding over the last 5 days of self-administration (+SEM). *=p<0.05 
Forward locomotor activity 
Figure 4 shows the effect of an MDMA challenge injection (0.0, 5.0 mg/kg, i.p) 
on forward locomotor activity, with activity for 0.0 mg/kg MDMA taken from the second 
day of locomotor activity testing. ANOVA revealed significant interactions between 
MDMA dose and time in the master (F(29,87) = 4.24, p<.05), yoked MDMA (F(29,87) = 
4.29, p<.05), and yoked saline conditions (F(29,87) = 4.29, p<.05). A significant effect of 
MDMA dose was found in the master condition (F(1,3) = 10.49, p<.05), but not in the 
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yoked MDMA (F(1,3) = 9.03, ns), or yoked saline conditions (F(1,3) = 6.49, ns). There 
was a significant effect of time in the master (F(29,87) = 4.34, p<.05), yoked MDMA 
(F(29,87) = 3.53, p<.05), and yoked saline conditions (F(29,87) = 2.29, p<.05). Post hoc 
analyses showed a significant difference between saline and MDMA at multiple time 
points for the master (t20-t70), yoked MDMA (t15-t25, and t35-t60), and yoked saline 
conditions (t20, t30, t35, t45, t50, t65). 
 
Figure 4. Effect of challenge injection (0.0, 5.0 mg/kg, i.p) on forward locomotor activity 
in the master, yoked MDMA, and yoked saline conditions. Challenge injections were 
administered at time 0. Error bars represent SEM. * p < .05 compared to 0.0 mg/kg 
MDMA. 
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Time course data for forward locomotor activity following an MDMA challenge 
injection (5 mg/kg) are shown in figure 5. ANOVA revealed an interaction between time 
and self-administration condition (F(58,261) = 1.53, p<.05), and a significant main effect 
of time (F(29,261) = 9.97, p<.05), but no main effect of condition (F(2,9) = 2.12, ns). 
Post hoc Tukey tests revealed a significant increase in forward locomotor activity in the 
master condition, compared to yoked saline condition, at multiple time points (t25, t30, 
t40, t45, t55). 
 
Figure 5. Time course of data from figure 4 showing effect of an MDMA challenge 
injection (5 mg/kg, i.p) on forward locomotor activity in each self-administration 
condition. The MDMA challenge was administered at time 0. Error bars represent SEM.* 
p < 0.05, master compared to yoked saline.  
Vertical locomotor activity 
Figure 6 shows the effect of MDMA dose (0.0, 5.0 mg/kg MDMA) on vertical 
locomotor (rearing) activity, with activity for 0.0 mg/kg MDMA taken from the second 
day of locomotor activity testing. ANOVA revealed a significant interaction between 
MDMA dose and time for the master (F(29,87) = 3.09, p<.05), yoked MDMA (F(29,87) 
= 3.47, p<.05), and yoked saline conditions (F(29,87) = 1.90, p<.05). No significant 
effect of MDMA dose was found in the master (F(1,3) = 8.71, ns), yoked MDMA (F(1,3) 
= 7.96, ns), or yoked saline group (F(1,3) = 0.96, ns), however a significant effect of time 
was found for the master (F(29,87) = 2.75, p<.05), yoked MDMA (F(29,87) = 3.82, 
p<.05), and yoked saline conditions (F(29,87) = 5.44, p<.05). Post hoc analyses showed a 
significant difference between 0.0 and 5.0 mg/kg MDMA doses at multiple time points 
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for the master (t25-t40, and t50) and yoked MDMA (t30-t45) conditions, but no 
significant differences were found in the yoked saline condition. 
Time course data following MDMA administration are shown in figure 7. 
ANOVA revealed an interaction between time and self-administration condition 
(F(58,261) = 1.83, p<.05) and a significant main effect of time (F(29,261) = 4.81, p<.05), 
but no main effect of self-administration condition (F(2,9) = 3.51, ns). Post hoc Tukey 
tests revealed a significant increase in in vertical activity in the master condition, 
compared to the yoked saline condition, at two time points (t25, t30), as well as a 
significant increase in vertical activity in the yoked MDMA condition, compared to the 
yoked saline condition, at multiple time points (t30, t35, t40, t45). 
 
Figure 6. Effect of MDMA challenge injection (0.0, 5.0 mg/kg, i.p) on vertical locomotor 
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activity in the master, yoked MDMA, and yoked saline conditions. Challenge injections 
were administered at time 0. Error bars represent SEM. * p < .05 compared to 0.0 mg/kg 
MDMA. 
 
 
 
 
 
 
 
Figure 7. Time course of data from figure 6 showing effect of an MDMA challenge 
injection (5 mg/kg, i.p) on vertical locomotor activity in each self-administration 
condition. The challenge MDMA injection was administered at time 0. Error bars 
represent SEM.* p < 0.05, master compared to yoked saline. # p < 0.05, yoked MDMA 
compared to yoked saline. 
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Figure 8. Quantification of c-fos density in brain structures after an MDMA challenge 
injection (5 mg/kg). Data are expressed as the mean number of Fos-IR cells/mm2 in each 
structure (+SEM). *p < 0.05, compared to yoked saline. 
In the two sub regions of the ventral striatum ANOVA revealed a significant main 
effect of self-administration condition in the nucleus accumbens core (F(2,9) = 9.68, 
p<.05), and no significant effect of self-administration condition in the nucleus 
accumbens shell (F(2,9) = 2.87, ns). Post hoc tests showed that c-fos density was 
significantly lower in the master condition compared to the yoked MDMA and yoked 
saline conditions, as shown in figure 9. 
In the three sub-regions in the prefrontal cortex ANOVA revealed a significant 
main effect of self-administration condition in the cingulate cortex (F(2,9) = 4.82, p<.05) 
and in the infralimbic cortex (F(2,9) = 7.85, p<.05), but no significant main effect of self-
administration condition in the prelimbic cortex (F(2,9) = 3.99, ns). As illustrated in 
figure 8, post hoc analyses showed, in the cingulate cortex, c-fos density was significantly 
lower in the master condition compared to the yoked MDMA and yoked saline 
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conditions, and in the infralimbic cortex c-fos density was significantly lower in the 
master and yoked MDMA conditions, compared to the yoked saline condition. 
 
Figure 9. Effect of self-administration condition on c-fos expression in the nucleus 
accumbens core following a challenge injection of 5.0 mg/kg MDMA. (A) Microscopy 
image of a coronal section of a rat brain after staining with neutral red. (B-D) higher-
magnification images (20x objective) of the boxed area depicted in A. (B) master, (C) 
Yoked MDMA, (D) Yoked saline group. 
B 
D 
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Part III: The relationship between behaviour and c-fos expression 
Figure 10 shows correlations between the MDMA-produced forward locomotor 
response and c-fos density in the areas of interest. Significant negative correlations 
between c-fos density and total ambulatory counts were found in the cingulate cortex and 
the infralimbic cortex, and a negative correlation between c-fos density and total 
ambulatory counts in the nucleus accumbens core approached significance.  
 
Figure 10. Correlations between total ambulatory counts and c-fos density in one 
subregion of ventral striatum (NAcC), and two sub-regions of the prefrontal cortex (Cg, 
IF). 
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 Figure 11 shows correlations between MDMA-produced vertical locomotor 
activity and c-fos density. Significant negative correlations were found between c-fos 
density and total rearing counts in the cingulate cortex and the infralimbic cortex, while 
negative correlations between c-fos density and total rearing counts in the nucleus 
accumbens core, and nucleus accumbens shell, approached significance. 
 
Figure 11. Correlations between total rearing counts and c-fos density in two subregions 
of ventral striatum (NAcC, NAcS), and two sub-regions of the prefrontal cortex (Cg, IF). 
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Discussion 
The main objective of this thesis was to determine whether MDMA-produced 
forward locomotor activity and vertical locomotor activity became sensitised following 
MDMA self-administration. Additionally, the relationship between MDMA-produced 
hyperactivity and c-fos expression in specific brain regions was determined. 
The first experiment compared the effect of method of MDMA exposure on the 
subsequent locomotor activating effects of MDMA. There was an MDMA-produced 
increase in forward locomotor activity in rats from all three conditions (MDMA self-
administration, yoked MDMA, and yoked saline) as has previously been reported 
(McCreary, Bankson, & Cunningham, 1999). Sensitisation was produced by MDMA 
exposure, as has also been previously reported (Ball, Budreau, & Rebec, 2006; Bradbury 
et al., 2012; Kalivas et al., 1998; Schenk & Bradbury, 2015; Spanos & Yamamoto, 1989). 
The magnitude of the sensitised response, however, depended on method of MDMA 
exposure. Specifically, after an MDMA challenge injection, forward locomotion was 
significantly increased only for the group that had received self-administered MDMA; the 
locomotor activating effect of MDMA in the group that received yoked infusions of 
MDMA was not significantly greater than the MDMA-produced increase in forward 
locomotion of the saline pre-exposed group. Given that previous research has reported 
sensitisation of MDMA-produced forward locomotion following repeated experimenter-
administered MDMA it was surprising that the yoked MDMA animals failed to show a 
sensitised locomotor response. This differential effect of MDMA exposure method might 
indicate that different neuroadaptations are produced by contingent vs non-contingent 
exposure to MDMA. 
There are data that indicate that, indeed, neurochemical effects of repeated drug 
exposure might depend on whether the drug is experimenter-administered or self-
administered (Dworkin et al., 1995; Hemby et al., 1997; Hemby et al., 1995; Stefanski et 
al., 1999). For example, following 25 days of cocaine exposure, an intravenous cocaine 
infusion produced greater extracellular DA levels in a group of rats that had self-
administered cocaine, compared to the rats that had received yoked cocaine delivery 
(Hemby et al., 1997). In the case of MDMA it has been reported that self-administration 
produced an augmented DA response to MDMA (Colussi-Mas et al., 2010). However, no 
studies have been conducted to compare MDMA produced DA efflux following self-
administration and yoked administration. If the DAergic response to MDMA is greater 
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after MDMA self-administration compared to yoked administration, as was seen with 
cocaine (Hemby et al., 1997), this could explain behavioural differences observed in the 
present study.  
 In addition to forward locomotor activity, the effect of method of MDMA 
exposure on subsequent MDMA-produced vertical locomotor activity was also assessed. 
As has been previously reported (O'Loinsigh, Boland, Kelly, & O'Boyle, 2001), acute 
administration of MDMA did not produce vertical locomotor activity in animals that were 
not previously exposed to MDMA. An increase in vertical locomotor activity was, 
however, evident in both groups that received MDMA exposure. This finding is 
consistent with findings from previous studies that also found an increase in vertical 
locomotor activity following repeated experimenter-administered (Lettfuss et al., 2013), 
or self-administered (Schenk & Bradbury, 2015) MDMA. Because increased vertical 
locomotor activity has been attributed to increased DA release (Thiel et al., 1999), an 
increase in vertical locomotor activity following repeated MDMA exposure may reflect 
the increase in MDMA-produced DA release produced following pre-exposure (Colussi-
Mas et al., 2010; Kalivas et al., 1998).  
 Alternatively, vertical locomotor activity might emerge as a result of 5HT deficits 
produced by repeated exposure to MDMA. Acute administration of MDMA produced 
elements of 5HT syndrome, including flat-body posture and forepaw treading (Spanos & 
Yamamoto, 1989),  behaviours that are incompatible with vertical locomotor activity. 
Repeated MDMA exposure attenuated MDMA-produced increases in extracellular 5HT 
levels, and resulted in tolerance to these 5HT-mediated behaviours (Baumann, Clark, 
Franken, et al., 2008). Although 5HT syndrome in response to MDMA has not been 
assessed after MDMA self-administration, the dosing regimen used in the present study 
has been reported to produce 5HT depletions (Do & Schenk, 2013). Therefore, tolerance 
to MDMA-produced 5HT syndrome behaviours might explain why rearing emerges 
following repeated MDMA exposure.  
 Taken together, these data suggest that repeated MDMA exposure resulted in 
sensitised forward and vertical locomotor activity in response to MDMA. It is possible 
that these sensitised responses could be explained by a reduction in the 5HT response 
and/or a sensitised DA response to MDMA. Such neuroadaptations would be consistent 
with previous findings that have shown an increase in MDMA-produced DA release 
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(Colussi-Mas et al., 2010), and a reduction in MDMA-produced 5HT release (Reveron et 
al., 2010) following MDMA self-administration.  
The second part of this study mapped MDMA-produced neuronal activation of 
cells as a function of MDMA exposure. Acute exposure to MDMA (Dragunow et al., 
1991; Hashimoto et al., 1997; Stephenson et al., 1999), cocaine (Ennulat et al., 1994; 
Graybiel et al., 1990), and amphetamine (Graybiel et al., 1990; Jaber et al., 1995) has 
been shown to increase c-fos expression in various brain regions including the dorsal 
striatum, NAc, and PFC. Repeated exposure to various psychostimulants resulted in an 
attenuation of this increase in c-fos expression (Ennulat et al., 1994; Hope et al., 1992; 
Jaber et al., 1995; Konradi et al., 1996), and similar effects were reported following 
repeated exposure to MDMA (Colussi‐Mas & Schenk, 2008). 
In the present study, repeated MDMA exposure produced a decrease in c-fos 
expression in the ventromedial and ventrolateral dorsal striatum, and in the infralimbic 
cortex, compared to yoked saline controls. Because vertical activity was sensitised in both 
MDMA exposure conditions (MDMA self-administration and yoked MDMA), the data 
suggest that the non-selective decrease in c-fos expression in these regions might be 
important for the expression of these sensitised behaviours. C-fos expression in the NAc 
core and the cingulate cortex was, however, selectively decreased by MDMA self-
administration. This might be relevant to the selective sensitised response following 
MDMA self-administration. A decrease in c-fos expression in the NAc shell was 
produced following cocaine self-administration (Larson et al., 2010; Zahm et al., 2010), 
suggesting that there might be different consequences depending on the drug that is self-
administered. In fact, methamphetamine-produced c-fos expression in the NAc was not 
altered at all following methamphetamine self-administration (Cornish et al., 2012). 
These findings are, however, difficult to interpret because Cornish et al. (2012) failed to 
invoke a withdrawal period. It is well documented that a withdrawal period is required for 
sensitisation of methamphetamine-produced locomotor activity (Hamamura et al., 1991; 
Nishikawa, Mataga, Takashima, & Toru, 1983). This might explain why Cornish et al. 
(2012) failed to show a sensitised behavioural response, and also failed to observe 
changes in c-fos expression.  
The PFC is also implicated in self-administration. Specifically, drug-produced 
hypofrontality of the PFC has been suggested to underlie the loss of inhibitory cognitive 
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control over drug seeking (Kalivas, 2009). There was a decrease in c-fos expression in the 
prelimbic cortex and cingulate cortex as a function of repeated MDMA exposure. Similar 
results have been reported following repeated cocaine exposure (Todtenkopf & Stellar, 
2000). While other self-administration studies have not focussed various sub-divisions of 
the PFC (Larson et al., 2010; Zahm et al., 2010), the present study measured c-fos in three 
sub-regions and highlights the importance of the cingulate cortex in the development of 
MDMA self-administration. This is a novel finding that suggests that the cingulate cortex 
might play an important role in sensitisation to the behavioural effects following MDMA 
self-administration. 
The NAc receives glutamatergic projections from the PFC, and disruption of these 
projections plays an important role in the development of compulsive drug-seeking 
(Kalivas, 2009). Thus, it is possible that changes in c-fos expression after MDMA self-
administration reflect neuroadaptations in the glutamate projections from the PFC to the 
NAc. Because c-fos is a general marker of neuronal activation it is not possible to identify 
the specific neurochemical systems that were activated by MDMA. Use of double 
labelling in future studies might provide more information. Alternatively, the impact of 
selective agonists on c-fos expression following MDMA self-administration would be 
informative.  
The current study used c-fos immunohistochemistry to identify neuronal 
activation following repeated exposure to MDMA. While this method has been regarded 
as extremely useful for mapping neural activity (Kovács, 1998) and has been used for 
studying effects of drugs of abuse (Harlan & Garcia, 1998), there are some limitations 
that must be taken into account. Since c-fos expression is low under basal conditions, 
immunohistochemistry permits the detection of neurons following recent activation. 
However, this approach does not allow for the detection of neurons that are under net 
synaptic inhibition, so there is risk of missing a potential decrease in neuronal activation. 
Furthermore, neurons with high activity do not always express c-fos (Kovács, 1998), 
leaving the possibility of an underestimation of c-fos expression in regions involved in 
the drug response. 
The combined investigation of c-fos expression and behavioural responses, 
however, provides important information concerning the relationship between brain and 
behaviour. The third part of the current study attempted to determine whether specific 
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changes in neural activation were correlated with forward and vertical locomotor activity. 
A negative relationship between forward and vertical locomotor activity and MDMA-
produced c-fos expression in the cingulate cortex and infralimbic cortex was found. 
Furthermore, the negative relationship between forward locomotor activity and c-fos 
expression in the nucleus accumbens approached significance, as did the negative 
relationship between vertical locomotor activity and c-fos expression in the NAc core and 
NAc shell. It is possible that these correlations would become significant if the sample 
size had been larger, however given the length of time required to conduct the current 
experiment and the large attrition rate, it was not possible to increase the sample size.  
The sensitisation of forward locomotor activity and vertical locomotor activity 
following repeated drug exposure have been attributed to enhanced DAergic 
neurotransmission (Brennan, Carati, Lea, Fitzmaurice, & Schenk, 2009; Thiel et al., 
1999). Accordingly, one might have expected c-fos expression to increase rather than 
decrease. One possible explanation is that the decrease in c-fos expression reflects 
MDMA-produced neuroadaptations in intracellular mechanisms.  
 
Figure 12. Schematic drawing to illustrate the molecular mechanism of c-fos expression. 
Image adapted from Cruz, Rubio, and Hope (2015). 
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Figure 12 shows the molecular mechanisms involved in c-fos expression. C-fos is 
a marker of post-synaptic activation, and is expressed following a cascade of molecular 
events. Strong neural activity at G-protein coupled receptors (GPCR), including 5HT and 
DA receptors, induces calcium influx (Kroeze, Sheffler, & Roth, 2003). Once the calcium 
influx is sufficient, ERK/MAPK are phosphorylated and activated via the Ras-Raf-
MEKK cascade. The phosphorylation of ERK/MAPK leads to the phosphorylation of 
Elk-1 that is associated with SRF, and also phosphorylates CREB via RSK. The c-fos 
promoter is then activated and c-fos is transcribed. Transcribed c-fos mRNA, and the 
translated protein, Fos, can then be used as a marker of strongly activated neurons. 
Phosphorylation of CREB can also occur via the cAMP/PKA pathway (Grady & 
Bunnett, 1997). The effect of activation of GPCR on CREB phosphorylation depends on 
the protein subunit. Stimulation of GPCR that are coupled to a Gs or Gq subunit activates 
the cAMP/PKA pathway, while stimulation of a GPCR coupled to a Gi subunit inhibits 
the cAMP/PKA pathway (Grady & Bunnett, 1997). Activation of the cAMP/PKA 
pathway increases CREB phosphorylation, and therefore enhances transcription of c-fos 
(Grady & Bunnett, 1997). Activation of D2 receptor subtypes inhibits the cAMP/PKA 
pathway, while activation of some 5HT (e.g. 5HT2A and 5HT2C) and DA (e.g. D1) 
receptor subtypes stimulates the cAMP/PKA pathway (Hoyer, Hannon, & Martin, 2002; 
Surmeier, Ding, Day, Wang, & Shen, 2007).  
Changes in MDMA-produced increases in extracellular DA or 5HT and the 
subsequent impact on activation of post-synaptic receptors would, therefore, be expected 
to alter c-fos expression. Repeated MDMA self-administration decreased MDMA 
stimulated 5HT release (Reveron et al., 2010), and increased DA release (Colussi-Mas et 
al., 2010), suggesting, in the absence of any relevant post-synaptic changes, a decrease or 
increase, respectively, of 5HT and DA receptor activation. This alone might explain the 
observed decrease in c-fos expression.  
Repeated exposure to MDMA, however, could provide an explanation for changes 
in c-fos expression. Repeated exposure to MDMA decreased the density of some 5HT 
receptors in rats (McGregor et al., 2003; Scheffel, Lever, Stathis, & Ricaurte, 1992) and 
humans (Reneman et al., 2002). Specifically, repeated MDMA administration produced a 
decrease in 5HT2A/2C receptor density in the striatum and PFC (McGregor et al., 2003). 
Because 5HT2A and 5HT2C receptors are coupled to a Gq G-protein subunit (Hoyer et al., 
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2002), activation would be expected to increase CREB phosphorylation. Thus, a decrease 
in 5HT2A and 5HT2C receptors would be expected to decrease c-fos expression. Consistent 
with this idea, a selective 5HT2A antagonist decreased cocaine-induced c-fos expression 
(Szucs, Frankel, McMahon, & Cunningham, 2005), but effects on MDMA-produced c-
fos expression have not been tested. 
Repeated exposure to MDMA also altered behavioural responses to D1 and D2 
receptor agonists (Bradbury et al., 2012). Sensitisation to the effects of a D2 agonist was 
pronounced following a sensitising regimen of MDMA exposure (Bradbury et al., 2012). 
Because D2 receptors are coupled to a Gi G-protein subunit (Surmeier et al., 2007), 
activation would be expected to reduce CREB phosphorylation. Therefore, an 
upregulation of D2 receptors would be expected to decrease c-fos expression.   
Alterations in c-fos expression produced by MDMA self-administration in the 
present study might, therefore, reflect changes in CREB phosphorylation, as has been 
demonstrated following repeated methamphetamine administration (McCoy et al., 2011). 
The effects of repeated MDMA on CREB phosphorylation in the striatum, NAc, or PFC 
has not yet been reported. Further research is needed in order to identify the effect of 
repeated MDMA exposure on CREB phosphorylation. 
In summary, the decrease in c-fos produced by repeated exposure to MDMA 
might be due to either changes in stimulated 5HT or DA release, the effects of such 
changes on receptor expression, or changes in intracellular mechanisms that influence the 
phosphorylation of CREB. It should be noted, however, that the regulation of c-fos 
expression is complex, and likely to be affected by various external variables. For 
example previous research suggested that c-fos expression is mediated by other 
transcription factors, such as ∆FosB (Renthal et al., 2008). ∆FosB bound to the c-fos 
promotor region, and reduced the transcriptional activity of c-fos in the striatum (Renthal 
et al., 2008). While it is well-documented that repeated exposure to psychostimulants 
increased ∆FosB in the striatum (Larson et al., 2010; Perrotti et al., 2005), the effect of 
MDMA exposure on ∆FosB has not yet been reported. If ∆FosB levels are increased as a 
result of repeated MDMA exposure this may explain the reduction in c-fos that was found 
in the present study.  
Interestingly, after a two week withdrawal period, evidence of MDMA-produced 
5HT syndrome behaviours started to reappear (Schenk & Bradbury, 2015). Measurement 
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of c-fos following this longer withdrawal period might help to tease apart the various 
possibilities for the mechanism behind this important recovery.  
Because of the correlational design of the present study, we can only conclude that 
the behavioural responses to MDMA are associated with changes in c-fos expression. 
Nevertheless, the expression of c-fos in the dorsal striatum, NAc, and PFC likely lead to 
long-term changes in the expression of target genes involved in neural activity. It is likely 
that neuroadaptations in these regions are important for regulating the development of 
MDMA self-administration. Thus, further research of the different neuroadaptations 
produced by MDMA self-administration should investigate the role of 5HT and DA in 
these regions.  
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